Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

[1]  G. Zimmerman,et al.  Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. , 1997, The Journal of clinical investigation.

[2]  P. Brûlet,et al.  Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation , 1993, Nature.

[3]  T. S. Wilkinson,et al.  Differential Regulation of Neutrophil-Activating Chemokines by IL-6 and Its Soluble Receptor Isoforms1 , 2004, The Journal of Immunology.

[4]  M. Neurath,et al.  Cutting Edge: Trans-Signaling via the Soluble IL-6R Abrogates the Induction of FoxP3 in Naive CD4+CD25− T Cells1 , 2007, The Journal of Immunology.

[5]  T. S. Wilkinson,et al.  Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. , 2001, Immunity.

[6]  G. Kollias,et al.  Interleukin 6 Is Required for the Development of Collagen-induced Arthritis , 1998, The Journal of experimental medicine.

[7]  P. Taylor,et al.  Oncostatin M Receptor-β Signaling Limits Monocytic Cell Recruitment in Acute Inflammation1 , 2008, The Journal of Immunology.

[8]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[9]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[10]  R. Kiesslich,et al.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.

[11]  J. Scheller,et al.  IL-6 transsignaling: the in vivo consequences. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[12]  C. Stewart,et al.  Leukaemia inhibitory factor and the regulation of pre-implantation development of the mammalian embryo. , 1994, Molecular reproduction and development.

[13]  Simon A. Jones,et al.  Shedding of the soluble IL‐6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP‐1 cells , 1998, European journal of immunology.

[14]  P. Marrack,et al.  Activation-Induced Inhibition of Interleukin 6–Mediated T Cell Survival and Signal Transducer and Activator of Transcription 1 Signaling , 2000, The Journal of experimental medicine.

[15]  G. Wong,et al.  TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination , 1998, Nature Medicine.

[16]  H. Tilg,et al.  Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. , 1994, Blood.

[17]  Stefan Rose-John,et al.  ADAM17: a molecular switch to control inflammation and tissue regeneration. , 2011, Trends in immunology.

[18]  L. Hennighausen,et al.  Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system , 2006, Nature Immunology.

[19]  J. Blay,et al.  Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients , 2003, British Journal of Cancer.

[20]  C. Fielding,et al.  A role for IL-27p28 as an antagonist of gp130-mediated signaling , 2010, Nature Immunology.

[21]  I. Wicks,et al.  Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. , 2006, Arthritis and rheumatism.

[22]  T. Vischer,et al.  Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. , 1997, The Journal of rheumatology.

[23]  A. Miyajima,et al.  Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice , 2004, Hepatology.

[24]  Y. Saeki,et al.  Interleukin 6 plays a key role in the development of antigen-induced arthritis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Bromberg.  Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.

[26]  M. Bissell,et al.  Targeting TACE-dependent EGFR ligand shedding in breast cancer. , 2007, The Journal of clinical investigation.

[27]  Simon A. Jones,et al.  Although IL-6 Trans-Signaling Is Sufficient To Drive Local Immune Responses, Classical IL-6 Signaling Is Obligate for the Induction of T Cell-Mediated Autoimmunity , 2010, The Journal of Immunology.

[28]  D. Cosman,et al.  Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor , 1991, Cell.

[29]  M. Neurath,et al.  Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. , 2011, The Journal of clinical investigation.

[30]  M. Sata,et al.  Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble–IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model , 2009, The Journal of Immunology.

[31]  R. Vejsada,et al.  Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth , 1995, Cell.

[32]  P. Heinrich,et al.  Soluble receptors for cytokines and growth factors: generation and biological function. , 1994, The Biochemical journal.

[33]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[34]  Jing Cui,et al.  Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci , 2010, Nature Genetics.

[35]  B. Klein,et al.  High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo , 1992, European journal of immunology.

[36]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[37]  D. Wallach,et al.  Soluble cytokine receptors are present in normal human urine , 1989, Journal of Experimental Medicine.

[38]  P. Rosenstiel,et al.  Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model* , 2011, Critical care medicine.

[39]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[40]  J. Kremer,et al.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.

[41]  P. Bongrand,et al.  The IL-6-Soluble IL-6Rα Autocrine Loop of Endothelial Activation as an Intermediate Between Acute and Chronic Inflammation: an Experimental Model Involving Thrombin , 2001, The Journal of Immunology.

[42]  L. Marinova-Mutafchieva,et al.  An anti‐inflammatory role for interleukin‐11 in established murine collagen‐induced arthritis , 1998, Immunology.

[43]  R. Kastelein,et al.  Understanding the IL-23-IL-17 immune pathway. , 2006, Trends in immunology.

[44]  Thomas Tüting,et al.  Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. , 2009, Cancer cell.

[45]  E. Choy.  RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists , 2009, Nature Clinical Practice Rheumatology.

[46]  H. Baumann,et al.  Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6. , 1991, The Journal of biological chemistry.

[47]  N. Sims.  gp130 signaling in bone cell biology: Multiple roles revealed by analysis of genetically altered mice , 2009, Molecular and Cellular Endocrinology.

[48]  J. Scheller,et al.  Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer , 2006, Journal of leukocyte biology.

[49]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[50]  A. Weyrich,et al.  Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. , 1997, The Journal of clinical investigation.

[51]  J. Scheller,et al.  Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis1 , 2009, The Journal of Immunology.

[52]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[53]  S. Kozma,et al.  Differences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor , 2010, The Journal of Immunology.

[54]  P. Musiani,et al.  Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. , 1997, The American journal of pathology.

[55]  M. Gerretsen,et al.  A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.

[56]  H. Einsele,et al.  In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. , 2011, Arthritis and rheumatism.

[57]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[58]  L. Ivashkiv,et al.  Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. , 2010, Arthritis and rheumatism.

[59]  S. Rose-John,et al.  Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 , 2003, The Journal of Immunology.

[60]  Simon A. Jones,et al.  Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61 , 2005, The Journal of Immunology.

[61]  Georg Schett,et al.  Cytokines in the pathogenesis of rheumatoid arthritis , 2007, Nature Reviews Immunology.

[62]  M. Bachmann,et al.  Averting inflammation by targeting the cytokine environment , 2010, Nature Reviews Drug Discovery.

[63]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[64]  Simon A. Jones,et al.  Brief Definitive Report C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding , 1999 .

[65]  David Gruben,et al.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.

[66]  M. Rincón,et al.  Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells1 , 2008, The Journal of Immunology.

[67]  S. Akira.  Roles of STAT3 defined by tissue-specific gene targeting , 2000, Oncogene.

[68]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[69]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[70]  P. Galle,et al.  IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-61 , 2000, The Journal of Immunology.

[71]  K. Shiota,et al.  Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[72]  P. Musiani,et al.  Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice , 1996, The Journal of experimental medicine.

[73]  C. Fielding,et al.  Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. , 2006, Arthritis and rheumatism.

[74]  P. Bongrand,et al.  Chemotactic agents induce IL‐6Rα shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF‐α‐converting enzyme (TACE) type , 2002 .

[75]  P. Meikle,et al.  Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance , 2010, Diabetologia.

[76]  C. Fielding,et al.  Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[77]  J. Saldanha,et al.  Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. , 1993, Cancer Research.

[78]  C. Begley,et al.  Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation , 1998, Nature Medicine.

[79]  Francesco Novelli,et al.  Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. , 2008, Seminars in cell & developmental biology.

[80]  P. Schirmacher,et al.  Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. , 1997, Journal of immunology.

[81]  Malcolm D. Smith,et al.  The Jak-STAT pathway in rheumatoid arthritis. , 2005, The Journal of rheumatology.

[82]  Andrew Filer,et al.  Predicting the development of RA in patients with early undifferentiated arthritis. , 2009, Best practice & research. Clinical rheumatology.

[83]  L. Ivashkiv,et al.  The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective? , 2003, Arthritis and rheumatism.

[84]  J. Scheller,et al.  Loss of CD4+ T Cell IL-6R Expression during Inflammation Underlines a Role for IL-6 Trans Signaling in the Local Maintenance of Th17 Cells , 2010, The Journal of Immunology.

[85]  C. Fielding,et al.  Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. , 2007, Blood.

[86]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[87]  I. Wicks,et al.  Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. , 2001, The Journal of clinical investigation.

[88]  A. Giraud,et al.  STAT3 as a prognostic marker in human gastric cancer , 2009, Journal of gastroenterology and hepatology.

[89]  Christopher A Hunter,et al.  Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10 , 2007, Nature Immunology.

[90]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[91]  B. Klein,et al.  Inhibiting IL-6 in human multiple myeloma. , 1992, Current topics in microbiology and immunology.

[92]  S. Melmed,et al.  Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. , 2002, Endocrinology.

[93]  D. Ahn,et al.  STAT3 expression in gastric cancer indicates a poor prognosis , 2009, Journal of gastroenterology and hepatology.

[94]  T. Nheu,et al.  Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling , 2005, Nature Medicine.

[95]  N. Udagawa,et al.  Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[96]  J. Scheller,et al.  The IL-6/sIL-6R complex as a novel target for therapeutic approaches , 2007, Expert opinion on therapeutic targets.

[97]  C. Fielding,et al.  IL-6 Regulates Neutrophil Trafficking during Acute Inflammation via STAT31 , 2008, The Journal of Immunology.

[98]  E. Wolf,et al.  The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL- 6 and prolongation of the plasma half-life of IL-6 , 1996, The Journal of experimental medicine.

[99]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[100]  N. Krug,et al.  The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. , 2005, The Journal of clinical investigation.

[101]  M. Feldmann,et al.  Development of anti-TNF therapy for rheumatoid arthritis , 2002, Nature Reviews Immunology.

[102]  V. Poli,et al.  Interleukin 6 Dependence of Anti-DNA Antibody Production: Evidence for Two Pathways of Autoantibody Formation in Pristane-induced Lupus , 1998, The Journal of experimental medicine.

[103]  R. Kurzrock,et al.  Interleukin‐6 and its receptor in cancer , 2007, Cancer.

[104]  S. Rose-John,et al.  Inhibition of T Cell Apoptosis in the Aqueous Humor of Patients with Uveitis by IL-6/Soluble IL-6 Receptor trans-Signaling , 2004, The Journal of Immunology.

[105]  R. Zinkernagel,et al.  Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.

[106]  J. Karras,et al.  STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. , 2008, Journal of Clinical Investigation.

[107]  W. Wood,et al.  Cardiotrophin-1 , 1995, The Journal of Biological Chemistry.

[108]  T. Kishimoto.  IL-6: from its discovery to clinical applications. , 2010, International immunology.

[109]  M. Feldmann,et al.  Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[110]  A. Coombs,et al.  Actemra poised to launch IL-6 inhibitors , 2008, Nature Biotechnology.

[111]  I. McInnes,et al.  Interleukin 27 attenuates collagen-induced arthritis , 2008, Annals of the rheumatic diseases.

[112]  K. Yasukawa,et al.  Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. , 1992, Journal of immunology.

[113]  C. Hunter.  New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions , 2005, Nature Reviews Immunology.

[114]  T. Kishimoto,et al.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial , 2008, The Lancet.

[115]  S. Chevalier,et al.  CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex , 2000, Nature Neuroscience.

[116]  C. Libert,et al.  Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. , 2010, Cell metabolism.

[117]  Simon A. Jones,et al.  The soluble interleukin 6 receptor: mechanisms of production and implications in disease , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[118]  C. Fielding,et al.  Viral IL-6 Blocks Neutrophil Infiltration during Acute Inflammation1 , 2005, The Journal of Immunology.

[119]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[120]  O. Cummings,et al.  Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. , 2009, Lung cancer.

[121]  T. Mcclanahan,et al.  WSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27 , 2004, The Journal of Immunology.

[122]  W. B. van den Berg,et al.  Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. , 2004, Arthritis and rheumatism.

[123]  N. Nishimoto,et al.  Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.

[124]  T. Schnitzer,et al.  Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis , 2001, Arthritis research.

[125]  C. Benoist,et al.  Critical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-induced Arthritis , 2002, The Journal of experimental medicine.

[126]  M. Neurath,et al.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.

[127]  K. Kallen.  The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. , 2002, Biochimica et biophysica acta.

[128]  K. Frei,et al.  IL‐6‐deficient mice resist myelin oligodendrocyte glycoprotein‐induced autoimmune encephalomyelitis , 1998, European journal of immunology.

[129]  A. Miyajima,et al.  Oncostatin M deficiency leads to thymic hypoplasia, accumulation of apoptotic thymocytes and glomerulonephritis , 2009, European journal of immunology.